This study showed that upregulated miR-200c could partially resensitize the primary resistant NSCLC cell lines to gefitinib and suppress the activation of PI3K/AKT and MEK/ERK pathways. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.